drugset / Trial / NCT03638011

A Comparison of the Post-C/S Analgesic Effects of Neuraxial Duramorph vs Bilateral TAP Block With Liposomal Bupivacaine

NCT03638011 ↗

Phase 4 Terminated 71 enrolled Maimonides Medical Center
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective is to reduce or eliminate the use of all narcotics/opiates for post Cesarean section pain management. The investigators hypothesize that in comparison with epidural or intrathecal Duramorph, a TAP block with liposomal bupivacaine (Exparel) will provide better, longer-acting pain control and will significantly reduce the use of post-operative IV or p.o. opiates. This is a prospective, randomized clinical trial.

Timeline

Start
2018-09-25
Primary completion
2020-03-31
Completion
2020-06-30

Outcome

Outcome not reported

Stopped: “Standard of Care changed due to COVID-19 and thus had to stop the study.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupivacaine Other / unclassified 266 mg —
Comparator Bupivacaine Other / unclassified — Other

Indications

No indication recorded.